体腔循环灌注热化疗与腹腔化疗治疗恶性腹腔积液疗效比较

目的 比较体外循环热灌注化疗与腹腔化疗治疗恶性腹腔积液的疗效.方法 62例恶性腹腔积液患者完全随机分为观察组(30例)和对照组(32例).观察组采用TRL-2000体腔循环热化疗系统行腹腔热疗,腹腔内温度达41～43℃,给予顺铂60～80 mg、地塞米松10 mg注入腹腔,体腔循环持续60 min；对照组给予腹腔注入顺铂60～80 mg.2组均2次/周,治疗2周.观察2组的疗效及不良反应.结果 观察组有效率90.0％( 27/30),卡氏评分改善80.0％( 24/30)；对照组有效率43.7％ (14/32),卡氏评分改善40.6％ (13/32),2组比较差异均有统计学意义(均P＜0.05).2组白细胞、肝肾功损伤及恶心呕吐、腹痛等不良反应发生率差异无统计学意义(P＞0.05).结论 体腔循环灌注热化疗治疗恶性腹腔积液疗效好,患者生活质量提高较明显,患者可以耐受不良反应.

Malignant seroperitoneum treated by abdominal hyperthermic perfusion with intraperitoneal chemotherapy

Objective To observe the efficacy of abdominal hyperthermic perfusion with intraperitoneal chemotherapy in patients with malignant seroperitoneum. Methods All 62 patients were divided into observation group （30 cases ） and control group （32 cases ） randomly. Observation group underwent abdominal hyperthermie perfusion and intraperitoneal chemotherapy with eisplatin. Control group was treated with intraperitoneal chemotherapy through peritoneal pipe. Both were given eisplatin 60 - 80 mg twice a week. The responses of seroperitoneum and adverse events were observed. Results The total response rate of seroperitoneum in observation group was 90. 0% （ 27/30 ）, the improvement rate of KPS was 80.0% （ 24/30 ）, while those in control group was 43.7% （14/32） and 40. 6% （13/32）respectively. The difference between the 2 groups were statistically significant difference （ P 〈 0. 05 ）. The incidence rate of white blood cells, liver and kidney function damage and nausea and vomiting, abdominal pain and other adverse reactions in 2 groups had no statistically significant difference （ P 〉 0. 05 ）. Conclusion Abdominal hyperthermie perfusion combined with intraperitoneal chemotherapy have good efficacy and safety in treating malignant seroperitoneum.